Neuroscientific Biopharmaceuticals (ASX:NSB) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Neuroscientific Biopharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Neuroscientific Biopharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Neuroscientific Biopharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Neuroscientific Biopharmaceuticals's Cash-to-Debt or its related term are showing as below:

ASX:NSB' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 6 years, Neuroscientific Biopharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

ASX:NSB's Cash-to-Debt is ranked better than
99.93% of 1464 companies
in the Biotechnology industry
Industry Median: 7.685 vs ASX:NSB: No Debt

Neuroscientific Biopharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Neuroscientific Biopharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Neuroscientific Biopharmaceuticals Cash-to-Debt Chart

Neuroscientific Biopharmaceuticals Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Neuroscientific Biopharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial									No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Neuroscientific Biopharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Neuroscientific Biopharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuroscientific Biopharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuroscientific Biopharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Neuroscientific Biopharmaceuticals's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Neuroscientific Biopharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Neuroscientific Biopharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Jun. 2024 is calculated as:

Neuroscientific Biopharmaceuticals had no debt ⁽¹⁾.

Neuroscientific Biopharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Neuroscientific Biopharmaceuticals had no debt ⁽¹⁾.

Neuroscientific Biopharmaceuticals (ASX:NSB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Neuroscientific Biopharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Neuroscientific Biopharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuroscientific Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuroscientific Biopharmaceuticals Ltd (ASX:NSB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

a Street, Suite 5, Cottesloe, Perth, WA, AUS, 6011

Website

https://www.neuroscientific.com

Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.

Neuroscientific Biopharmaceuticals Headlines

No Headlines

Neuroscientific Biopharmaceuticals (ASX:NSB) Cash-to-Debt : No Debt (1) (As of Dec. 2024)